National Institute on Drug Abuse; Notice of Closed Meetings, 65696 [2023-20693]

Download as PDF 65696 Federal Register / Vol. 88, No. 184 / Monday, September 25, 2023 / Notices 20852, (240) 747–7530, mairi.noverr@ nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: September 19, 2023. Tyeshia M. Roberson-Curtis, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2023–20656 Filed 9–22–23; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings ddrumheller on DSK120RN23PROD with NOTICES1 Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Population Assessment of Tobacco and Health (PATH) Study. Date: October 31, 2023. Time: 12:00 p.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Shareen Iqbal, Ph.D., M.P.H., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 443–4577, shareen.iqbal@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; NIDA– K Alternate SEP. Date: November 3, 2023. Time: 12:00 p.m. to 1:45 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Marisa Srivareerat, Ph.D., Scientific Review Officer, Scientific Review VerDate Sep<11>2014 20:11 Sep 22, 2023 Jkt 259001 Branch, Office of Extramural Policy, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 435–1258, marisa.srivareerat@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; NIDA Animal Genomics and Functional Validation/Characterization of Genes/ Variants in SUD. Date: November 27, 2023. Time: 10:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 827–4471, ramadanir@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: September 20, 2023. Tyeshia M. Roberson-Curtis, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2023–20693 Filed 9–22–23; 8:45 am] BILLING CODE 4140–01–P Pandemic Preparedness (ReVAMPP) Centers for Flaviviridae and Togaviridae (U19 Clinical Trial Not Allowed). Date: October 24–25, 2023. Time: 10:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3F30, Rockville, MD 20892 (Virtual Meeting). Contact Person: Scott Jakes, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3F30, Rockville, MD 20852, (240) 669–5931, jakesse@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: September 20, 2023. Tyeshia M. Roberson-Curtis, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2023–20695 Filed 9–22–23; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Request for Information on the DRAFT Scientific Integrity Policy of the National Institutes of Health AGENCY: National Institutes of Health, HHS. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Research and Development of Vaccines and Monoclonal Antibodies for PO 00000 Frm 00047 Fmt 4703 Sfmt 4703 ACTION: Request for information. The National Institutes of Health (NIH) is soliciting comments and suggestions from the public on the DRAFT ‘‘Scientific Integrity Policy of the National Institutes of Health’’ (DRAFT NIH Scientific Integrity Policy). The DRAFT NIH Scientific Integrity Policy codifies NIH’s long-standing expectations to preserve scientific integrity throughout all NIH activities, establishes key roles and responsibilities for those who will lead the agency’s scientific integrity program, and, as appropriate, establishes relevant reporting and evaluation mechanisms. DATES: The DRAFT ‘‘Scientific Integrity Policy of the National Institutes of Health’’ is open for public comment for a period of 45 days. To ensure consideration, comments must be submitted in writing by November 9, 2023. ADDRESSES: Comments may be submitted electronically at https:// osp.od.nih.gov/comment-form-draftscientific-integrity-policy-for-thenational-institutes-of-health/. SUMMARY: E:\FR\FM\25SEN1.SGM 25SEN1

Agencies

[Federal Register Volume 88, Number 184 (Monday, September 25, 2023)]
[Notices]
[Page 65696]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-20693]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Population Assessment of Tobacco and Health (PATH) 
Study.
    Date: October 31, 2023.
    Time: 12:00 p.m. to 2:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Shareen Iqbal, Ph.D., M.P.H., Scientific Review 
Officer, Scientific Review Branch, Division of Extramural Research, 
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, 
MSC 6021, Bethesda, MD 20892, (301) 443-4577, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; NIDA-K Alternate SEP.
    Date: November 3, 2023.
    Time: 12:00 p.m. to 1:45 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Marisa Srivareerat, Ph.D., Scientific Review 
Officer, Scientific Review Branch, Office of Extramural Policy, 
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, 
MSC 6021, Bethesda, MD 20892, (301) 435-1258, 
[email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; NIDA Animal Genomics and Functional Validation/
Characterization of Genes/Variants in SUD.
    Date: November 27, 2023.
    Time: 10:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review 
Officer, Scientific Review Branch, Division of Extramural Research, 
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, 
MSC 6021, Bethesda, MD 20892, (301) 827-4471, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse and Addiction Research Programs, National 
Institutes of Health, HHS)

    Dated: September 20, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-20693 Filed 9-22-23; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.